# 1. Financial Performance ## A. Key Figures * Revenue: ₹602.9 Cr consolidated Q3 FY'26 (+8%) · ₹1,846.6 Cr 9M FY'26 (+8%) * EBITDA: ₹56.3 Cr Q3 FY'26 (–10%) · ₹215.0 Cr 9M FY'26 (+9%) * **PAT:** **₹40.5 Cr** Q3 FY'26 (+58%) * EBITDA Margin: 9.3% Q3 FY'26 · 11.6% 9M FY'26 * PAT Margin: 6.7% Q3 FY'26 ## B. Profitability Trends * **Significant Bottom-Line Outperformance:** PAT surged nearly 60% despite flat EBITDA, driven by **non-operating gains or tax benefits**, indicating strong earnings quality divergence. * **Inventory-Driven Margin Drag:** Gross margin compressed by **~100 bps** in Q3 due to sale of inventory with high raw material cost content, creating a **₹6 Cr headwind**. * **Margin Recovery Roadmap:** Management targets restoration of EBITDA margins to **12–13%** in the near term, with a long-term goal of **14–15%**, supported by backward integration now at **12% margin contribution for antidiabetic APIs**. ## C. Margin Pressures * **Demand and Mix Headwinds:** Weak antibiotic demand reduced capacity utilization and pricing power, while lower export content—historically higher-margin—weighed on standalone profitability. * **Path to 36% API Margin:** Standalone API gross margin target of **36% by FY'27** hinges on regulated market expansion, full ramp-up of the **D. S. FDA-compliant E22 plant**, and cost control via salicylic acid integration. ## D. Balance Sheet * **Debt Structure Clarity:** Total consolidated debt stands at **₹540 Cr**, with standalone accounting for **₹392 Cr**; debt is evenly allocated across divisions. * **Production Underutilization:** ~**₹30 Cr** of Q3 sales came from finished goods inventory drawdown, reflecting subdued operational throughput. * **Plant-Level EBITDA Loss:** The **₹5 Cr EBITDA loss** in the quarter was entirely attributable to the salicylic acid and Sayakha plants, highlighting ongoing startup or ramp-up challenges. --- # 2. Segment & Product Performance ## A. Key Figures * **Formulation Revenue:** **₹6 Cr** Q3 FY'26 (+58% YoY) · **67% from exports** * **Volume & Rate Impact:** **7% volume growth** YoY · **5% negative rate variance** ## B. API Revenue Mix & Strategy * **Strategic Forward Integration:** Metformin remains a core focus, with U.S. DMF filing underway and plans for ANDA submission via Pinnacle to capture **regulated market upside and higher-margin sales**. * **CDMO Expansion:** Contract manufacturing with MNCs is expanding; backward integration in **chlorosulfonation chemistry** provides a platform for CDMO/Spec Chem synergies and cost-efficient operations. * **Salicylic Acid Monetization:** Technology piloted and **salicylate block launch expected within 1–2 quarters**, unlocking value in cosmetics, healthcare, and fragrance end-markets. ## C. Formulation Growth * **Export-Led Momentum:** Formulations delivered strong YoY growth on robust export demand, particularly in higher-value segments, despite pricing headwinds. * **Niche Portfolio Build:** Strategic emphasis on **oncology and cardio-diabetic formulations**, including products based on in-house APIs, to enhance margins and differentiation. ## D. Oncology Pipeline * **Near-Term Commercialization:** U.S. FDA-approved oncology facility in Baddi set to begin **commercial sales in Q4 FY'26**, marking transition from pre-revenue stage. * **High-Growth Trajectory:** Oncology formulations projected to represent **~40% of total formulation revenue over next 3 years**, supported by **40–50% of formulation capex** allocation. * **Regulatory Leverage:** European approvals for Baddi OSD facility to accelerate expansion into regulated markets beyond oncology. --- # 3. Capacity & Utilization ## A. Key Figures * **Sayakha Utilization:** **30%** in Q1 FY26 (target: **50%** by Mar–Apr 2026 · **80–90%** within 12 months) * **EBITDA Drag:** **₹8–15 Cr** from shutdowns and ramp-up activities (Q3 FY26) * **Full-Scale EBITDA (Sayakha):** **>₹50 Cr** projected at full ramp * **Capex Guidance:** **₹150–200 Cr/year** for next two years · **~₹200 Cr** for current year * **Metformin Capacity:** Current: **1,450–1,500 T/month** · Expanded: **1,800–1,900 T/month** · Long-term: **2,500–3,000 T/month** * **Oncology Investment:** **₹200 Cr** total project cost (capex + development) · **₹50–60 Cr/year** for 3 years in R&D/regulatory * Oncology Capacity: 300 million pills planned production capacity ## B. Greenfield Ramp-Up * **Ramp-Up Headwinds:** New facilities and a one-time plant shutdown constrained output and profitability, creating a material EBITDA and PBT drag. * **Sayakha Progress:** Facility ramp-up is on track with smooth scale-up to 30% utilization in first quarter, supported by over 50% captive consumption and upcoming cogen boiler commissioning. * **Margin Recovery Path:** Gross margin improvement hinges on stabilization of salicylic acid plant and resumption of European supply, with cautious ramp due to revised product specs. * **Technology Evaluation:** Company is assessing new salicylic acid technology for broader deployment despite stable core chemistry operations. ## C. Plant Utilization Rates * **Broad Utilization Pressure:** API and FTF capacity use declined 4–5% QoQ due to transient issues now resolved; low utilization impacted operating leverage in Q3. * **Tarapur Salicylic Plant:** Production stabilized above 300 T/month with improved waste management, though December quarter utilization lagged targets. * **Formulation Mix:** 90% of tablet capacity located in general plant; non-oncology products dominate current physical output. ## D. Future Capacity Targets * **Expansion Pipeline:** Capex to drive growth in cardiovascular, antifungal, and CDMO segments, leveraging methylamine and chlorosulfonation chemistries from Sayakha. * **Oncology Buildout:** Dedicated investment supports brownfield expansions and a 30-crore-pill capacity platform, with sustained R&D spend to build regulatory pipeline. * **Global Metformin Share:** India’s share of global metformin capacity increased from 12–13% to over 15% post-expansion. --- # 4. Export & Geography Mix ## A. Key Figures * **Standalone Revenue:** **INR530.0 Cr** (88% of consolidated) * **Export Contribution:** **37%** of standalone revenue ## B. International Revenue * **Export-Led Growth Strategy:** Formulations in international markets are a key growth and margin driver, underpinned by IP ownership and out-licensing model in regulated geographies. * **Strategic Market Expansion:** Increasing penetration in European markets is a core focus, supported by active regulatory filings and pre-established **B2B partnerships** in target regions. * **Dossier-Driven Model:** In international markets, the company retains full IP rights and develops dossiers, while local partners handle marketing and distribution. ## C. Regulated Market Entry * **Regulatory Momentum:** European approvals progressing on track, with **EU GMP certification secured for both oncology and general oral solid dosage units** at the Baddi facility. * **Facility Readiness:** Ongoing audits and inspections demonstrate compliance readiness for regulated and semi-regulated markets. --- # 5. Cost & Supply Chain ## A. Key Figures * **Captive Supply:** **10%–15%** current coverage for antidiabetic intermediates · **full self-reliance** expected in next few quarters * **Project IRR:** **>20%** for salicylic acid backward integration ## B. Raw Material Impact * **Strategic Self-Reliance:** Accelerating backward integration to achieve full captive supply of key antidiabetic intermediates, enhancing supply chain resilience and reducing external dependency. * **Focused Integration:** Methylamines capacity dedicated exclusively to **metformin API**, not gliptins, aligning with targeted cost and supply control. * **Margin Upside:** Full-scale integration expected to lift gross contribution by **a couple of percentage points**, despite volatile input markets. ## C. China Supply Delays * **Import Disruptions:** Shipments from China delayed, extending lead times and amplifying cost pressures on production. --- # 6. Risks & Regulatory ## A. Chinese Dumping * **Ongoing Pricing Pressure:** Chinese dumping of salicylic acid persists, continuing to weigh on API prices despite slight improvement in realizations from favorable dollar exchange rates. * **Antidumping Action Imminent:** The company will file for antidumping duties by end-Q1, citing eligibility now met; outcome expected in **6 to 9 months**. * **Precedent for Success:** Management draws parallels to past metformin and ciprofloxacin cases, where antidumping relief enabled sustainable profitability post-entry barriers. * **Strategic Entry Challenge:** Aggressive Chinese price undercutting coincided with the company’s market entry, viewed as a **temporary barrier** to deter new Indian producers. * **Quality & Process Resilience:** Process adjustments implemented to maintain quality standards amid evolving physical chemistry technologies in salicylic acid production. ## B. Pricing Pressures * **Near-Term Realization Decline:** API pricing declined **2% to 5%** QoQ in the December quarter, led by weakness in the antibiotic segment. * **Mitigation via MIP:** Company exploring Minimum Import Price (MIP) applications in select cases to support realization under import parity pricing mechanisms. --- # 7. Guidance & Outlook ## A. Key Figures * **Volume Growth (FY '27):** **12%–15%** (driven by new projects) * **Existing Product Line Growth:** **Single-digit** volume increase expected ## B. Volume Projections * **New Projects to Lead Expansion:** FY '27 volume growth will be primarily driven by ramp-up of **salicylic acid** and **Sayakha methyl amines**, offsetting slower growth in mature lines. * **Greenfield Momentum:** Delayed FY '26 growth is now materializing, with smooth execution supporting the upward volume trajectory. ## C. Margin Recovery * **Inflection Achieved:** Business has turned a corner, with stabilizing prices and volume momentum, as evidenced by **encouraging January sales trends**. * **Path to Profitability:** EBITDA impact shifting from negative to positive, with **higher capacity utilization** and **improved product mix** set to drive margin expansion in coming quarters. * **Strategic Foundation Laid:** Prior investments are converging to enable a **new phase of growth**, underpinning confidence in sustained recovery.